Side-by-side · Research reference
AOD-9604vsSemax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed10/47 cited
BHuman-MechanisticDraft12/39 cited
AOD-9604
HGH 176-191 · β3-AR Lipolytic
SQ · Abdomen · Daily fasted
Semax
Cognitive enhancer · Russian Pharma
Intranasal · 2–3×/day during cognitive demand
01Mechanism of Action
Parameter
AOD-9604
Semax
Primary target
β3-adrenergic receptor (proposed)Ng 2008
BDNF / NGF expression + monoamine modulationKaplan 2017
Pathway
β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2008
↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017
Downstream effect
Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001
Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017
Feedback intact?
No GH-axis or IGF-1 feedback
—
Origin
Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2008
Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017
Antibody development
—
—
02Dosage Protocols
Parameter
AOD-9604
Semax
Standard dose
250–300 mcg / dayHeffernan 2001
Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.
200–600 mcg / dose intranasalKaplan 2017
Frequency
Once daily, fasted
2–3× per day during cognitive demand
Lower / starter dose
150 mcg / day
100 mcg / dose
Evidence basis
Phase 2 trials + animal-strongHeffernan 2001Ng 2008
Human-mechanistic + Russian clinicalKaplan 2017
Duration
8–12 weeks per cycle
10–14 day cycles, repeated PRN
Reconstitution
Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Timing
Morning fasted preferred (pre-cardio)
Aligns with circadian lipolysis.
Morning + early afternoon
Half-life
~30 min plasma
Short plasma; CNS effect lasts ~3–6 hr
04Side Effects & Safety
Parameter
AOD-9604
Semax
Injection site reaction
Mild erythema
—
GI symptoms
Rare mild nausea
—
Cardiovascular
Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)
—
Cancer risk
No GH/IGF-1 axis activity → lower theoretical risk vs HGH
—
Pregnancy / OB
Avoid
Avoid
Nasal irritation
—
Mild burning or congestion (transient)
Sleep disruption
—
Late-day dosing may interfere with sleep
Headache
—
Uncommon, transient
Long-term safety
—
Limited Western RCT data
Absolute Contraindications
AOD-9604
- ·Pregnancy / breastfeeding
- ·Severe cardiovascular disease (caution with β-receptor agonists)
Semax
- ·Pregnancy / breastfeeding
Relative Contraindications
AOD-9604
- ·Concurrent β-blocker therapy (theoretical antagonism)
- ·Pheochromocytoma
Semax
- ·Active psychiatric instability
- ·Concurrent strong stimulants
05Administration Protocol
Parameter
AOD-9604
Semax
1. Reconstitution
Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Injection site
SQ — abdomen preferred. Rotate sites.
Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.
3. Timing
Morning, fasted, ideally pre-cardio for amplified fat oxidation.
Morning + early afternoon. Avoid evening (sleep disruption).
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
Refrigerate after reconstitution; light-protected.
5. Needle
29–31G, 4–8 mm insulin syringe.
Cycle on/off to avoid neurochemical adaptation.
06Stack Synergy
AOD-9604
+ MOTS-c
ModerateAOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.
- AOD-9604
- 250–300 mcg SQ · morning fasted (daily)
- MOTS-c
- 5 mg SQ · 2–3× per week (pre-workout)
- Primary benefit
- Fat mobilisation + mitochondrial oxidation, no IGF-1 concern
Semax
+ Selank
ModerateSemax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.
- Semax
- 200–600 mcg intranasal · morning + afternoon
- Selank
- 150–300 mcg intranasal · midday + early evening
- Primary benefit
- Cognitive enhancement + stress mitigation